ISRCTN15903698终止1 期
A Phase I/Ib Trial of the Oral Hedgehog inhibitor, LY2940680, in Combination with Weekly Paclitaxel in Patients with Platinum-Resistant, Recurrent Ovarian Cancer or Recurrent, Advanced, Solid Tumours: open-label, non-randomised, multi-centre, dose escalation trial
HS Greater Glasgow and Clyde0 个研究点目标入组 16 人开始时间: 2015年2月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Inclusion criteria of the dose escalation phase:
- •Histologically or cytologically confirmed advanced solid tumours refractory to standard therapy or for whom weekly paclitaxel is considered, by the investigator, to be an appropriate therapy.
- •Inclusion criteria of the dose expansion phase:
- •1. Histologically confirmed high grade serous or G3 endometrioid epithelial ovarian, fallopian tube or primary peritoneal cancer with progressive or recurrent disease (patients with carcinosarcoma are eligible but mucinous, clear cell carcinoma and grade 1 or 2 tumours are not eligible). Progression may be defined radiologically by RECIST 1.1 or by CA125 criteria in combination with clinical symptoms or signs indicative of progression. Asymptomatic rise of CA125 alone will not be defined as progressive disease. Progression of disease must have occurred within 6 months of the last dose of platinum chemotherapy.
- •2. = 1 previous platinum based chemotherapy. This may have been given in the adjuvant setting.
- •3. No previous treatment with single agent weekly paclitaxel for relapsed disease. Weekly paclitaxel may have been given in the first line setting if given in combination with platinum chemotherapy.
- •4. No contra-indication to an image guided biopsy and tumour amenable to image guided biopsy.
- •5. Measurable or non-measurable disease.
- •6. Patients must have archival formalin-fixed paraffin-embedded tissue from their original diagnosis available for the purposes of translational research.
- •7. Patients with synchronous tumours e.g. ovarian and endometrial or history of prior malignancy are eligible provided that there is biopsy evidence that the disease measurable on CT and/or MRI is ovarian in origin
- •The following inclusion criteria will be required for all patients:
- •1. Written informed consent
- •2. Performance status =2 (ECOG)
- •3. Estimated life expectancy = 3 months
- •4. Age = 18 years
- •5. Adequate haematological, renal and hepatic function as defined by:
- •5.1Haemoglobin (Hb)> 10g/dl
- •5.2Neutrophil Count> 1.5 x 109/l
- •5.3Platelets> 100 x 109/l
- •5.4INR <2 x ULN and prothrombin time and activated partial thromboplastin time < 1.5 x ULN in the absence of therapeutic anticoagulation
- •5.5Glomerular Filtration rate of > 50 mL/ min (calculated using the Wright formula or measured by EDTA clearance)
- •5.6Total bilirubin =1.5 x ULN and ALT and AST = 2.5 x ULN
- •6. No history of grade 2 peripheral neuropathy at any time during prior treatment and no greater than grade 1 residual peripheral neuropathy.
- •7. No use within the last 7 days of or requirement to continue medications that are strong inhibitors of CYP3A4.
- •8. No prior treatment with LY2940680 or other Hedgehog pathway inhibitor.
- •9. Female patients with reproductive potential must have a negative serum pregnancy test within 7 days of trial enrolment and agree to use an effective double barrier method of contraception during and for 6 months after last dose of treatment. Male patients of childbearing potential and their female partner must also agree to use an effective double barrier method of contraception dur
排除标准
- •The exclusion criteria are covered by the negative inclusion criteria
研究者
相似试验
进行中（未招募）
1 期
Trial of a new drug to prevent the rejection which could occur after a transplantation.Adult patiens with sclerotic chronic graft-versus-host disease refractory to second-line treatment.MedDRA version: 20.0Level: HLTClassification code 10074474Term: Transplantation complicationsSystem Organ Class: 100000109195MedDRA version: 20.0Level: LLTClassification code 10067862Term: Allogeneic stem cell transplantationSystem Organ Class: 100000022080MedDRA version: 20.0Level: PTClassification code 10074555Term: Transplantation complicationSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsMedDRA version: 20.0Level: LLTClassification code 10018653Term: Graft-versus-host disease <GVHD>System Organ Class: 100000020501MedDRA version: 20.0Level: LLTClassification code 10067859Term: Allogenic stem cell transplantationSystem Organ Class: 100000022080EUCTR2017-000862-31-ESGrupo Español de Trasplante Hematopoyético y Terapia Celular (GETH)24
已完成
1 期
Phase-I Clinical Trial to study the Safety of oral drug Bioplatin in patients of Advanced metastatic Solid Tumours and those who are resistant to conventional treatmentsCTRI/2017/06/008778Rasayani Biologics Pvt Ltd14
已完成
2 期
Clinical trial phase II of oral hebal compoenent (BMP) in patient with multiple sclerosisMultiple Sclerosis.Demyelinating diseases of the central nervous systemG35, G36,IRCT138803241696N2Iran Rheumatism Center10
已完成
3 期
An open label clinical trial of an orally-dosed herbal formulation Zinova (Registered Trademark) for the prevention of dysmenorrhoea (menstrual pain).DysmenorrhoeaAlternative and Complementary Medicine - Herbal remediesReproductive Health and Childbirth - Menstruation and menopauseACTRN12612000149864Applied Science and Nutrition Pty. Ltd.20
未知
1 期
Phase I, Multiple Oral Dose Study to Evaluate the Tolerability and Pharmacokinetics of Favipiravir in Healthy VolunteersJPRN-jRCT2080222606Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)10